JP2017119710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017119710A5 JP2017119710A5 JP2017061022A JP2017061022A JP2017119710A5 JP 2017119710 A5 JP2017119710 A5 JP 2017119710A5 JP 2017061022 A JP2017061022 A JP 2017061022A JP 2017061022 A JP2017061022 A JP 2017061022A JP 2017119710 A5 JP2017119710 A5 JP 2017119710A5
- Authority
- JP
- Japan
- Prior art keywords
- psychotropic drug
- flecainide
- group
- modafinil
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940001470 psychoactive drug Drugs 0.000 claims 11
- 239000004089 psychotropic agent Substances 0.000 claims 11
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 claims 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 8
- 229960000449 flecainide Drugs 0.000 claims 8
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 6
- 229960001165 modafinil Drugs 0.000 claims 6
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 4
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 4
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 4
- 102000002512 Orexin Human genes 0.000 claims 4
- VWYANPOOORUCFJ-UHFFFAOYSA-N alpha-Fernenol Chemical compound CC1(C)C(O)CCC2(C)C3=CCC4(C)C5CCC(C(C)C)C5(C)CCC4(C)C3CCC21 VWYANPOOORUCFJ-UHFFFAOYSA-N 0.000 claims 4
- 229940025084 amphetamine Drugs 0.000 claims 4
- 229960004823 armodafinil Drugs 0.000 claims 4
- YFGHCGITMMYXAQ-LJQANCHMSA-N armodafinil Chemical compound C=1C=CC=CC=1C([S@](=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-LJQANCHMSA-N 0.000 claims 4
- 229960001948 caffeine Drugs 0.000 claims 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 4
- XNRHTMDHGDWBGP-UHFFFAOYSA-N carbamic acid;hydrochloride Chemical compound Cl.NC(O)=O XNRHTMDHGDWBGP-UHFFFAOYSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229960000299 mazindol Drugs 0.000 claims 4
- 229960001344 methylphenidate Drugs 0.000 claims 4
- 108060005714 orexin Proteins 0.000 claims 4
- -1 pitrisant Chemical compound 0.000 claims 4
- 229960003928 sodium oxybate Drugs 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000003291 dopaminomimetic effect Effects 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000003371 gabaergic effect Effects 0.000 claims 2
- 230000000848 glutamatergic effect Effects 0.000 claims 2
- 230000000742 histaminergic effect Effects 0.000 claims 2
- 230000000862 serotonergic effect Effects 0.000 claims 2
- 206010067125 Liver injury Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003667 flupirtine Drugs 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306074 | 2013-07-24 | ||
| EP13306074.9 | 2013-07-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528540A Division JP6192830B2 (ja) | 2013-07-24 | 2014-07-24 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018233114A Division JP6694497B2 (ja) | 2013-07-24 | 2018-12-13 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017119710A JP2017119710A (ja) | 2017-07-06 |
| JP2017119710A5 true JP2017119710A5 (https=) | 2017-08-17 |
| JP6453931B2 JP6453931B2 (ja) | 2019-01-16 |
Family
ID=48900920
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528540A Expired - Fee Related JP6192830B2 (ja) | 2013-07-24 | 2014-07-24 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
| JP2017061022A Expired - Fee Related JP6453931B2 (ja) | 2013-07-24 | 2017-03-27 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
| JP2018233114A Expired - Fee Related JP6694497B2 (ja) | 2013-07-24 | 2018-12-13 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528540A Expired - Fee Related JP6192830B2 (ja) | 2013-07-24 | 2014-07-24 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018233114A Expired - Fee Related JP6694497B2 (ja) | 2013-07-24 | 2018-12-13 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9750734B2 (https=) |
| EP (2) | EP3024458B1 (https=) |
| JP (3) | JP6192830B2 (https=) |
| KR (2) | KR101754045B1 (https=) |
| CN (1) | CN105579041B (https=) |
| AU (1) | AU2014295030B2 (https=) |
| BR (1) | BR112016001446A8 (https=) |
| CA (2) | CA2919140C (https=) |
| DK (1) | DK3024458T3 (https=) |
| ES (1) | ES2661647T3 (https=) |
| HR (1) | HRP20180487T1 (https=) |
| HU (1) | HUE037122T2 (https=) |
| IL (2) | IL243746A (https=) |
| MX (2) | MX365782B (https=) |
| PL (1) | PL3024458T3 (https=) |
| PT (1) | PT3024458T (https=) |
| RU (2) | RU2018122564A (https=) |
| TR (1) | TR201802302T4 (https=) |
| WO (1) | WO2015011246A1 (https=) |
| ZA (1) | ZA201601146B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX386469B (es) * | 2015-07-15 | 2025-03-18 | Theranexus | Uso de amitriptilina para el bloqueo de hemicanales en el cerebro y metodo para la potenciacion de este efecto in vivo. |
| ES3040411T3 (en) | 2018-03-22 | 2025-10-30 | Incarda Therapeutics Inc | A novel method to slow ventricular rate |
| CA3097378A1 (en) * | 2018-04-16 | 2019-10-24 | Alsar Ltd Partnership | Compositions and methods for sustained release of flecainide |
| EP3802881A4 (en) | 2018-06-11 | 2022-11-09 | Indiana University Research And Technology Corporation | METHODS OF EVALUATION AND EARLY DETECTION OF STRESS, SELECTION AND MONITORING OF TREATMENT, AND REUSE FOR PHARMACEUTICALS |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| EP3593822A1 (en) | 2018-07-13 | 2020-01-15 | Theranexus | Therapeutic and diagnostic applications of a new method of monitoring of neuroglial interaction memri) |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US11021410B2 (en) * | 2018-12-10 | 2021-06-01 | Purdue Research Foundation | Layer-wise agglomerated urea granules |
| KR102891439B1 (ko) | 2019-08-01 | 2025-11-25 | 인카다 테라퓨틱스, 인크. | 항부정맥 제제 |
| US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| US20220265666A1 (en) * | 2019-08-02 | 2022-08-25 | Praxis Precision Medicines, Inc. | Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression |
| CN111018694A (zh) * | 2019-12-12 | 2020-04-17 | 贵州省欣紫鸿药用辅料有限公司 | 一种氟卡尼的生产方法 |
| EP4164695A4 (en) * | 2020-05-13 | 2024-06-05 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR TREATING GJB2-ASSOCIATED HEARING LOSS |
| KR102390194B1 (ko) * | 2020-08-03 | 2022-04-25 | 셀라이온바이오메드 주식회사 | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 |
| WO2022170081A1 (en) * | 2021-02-05 | 2022-08-11 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001253825A (ja) | 2000-03-13 | 2001-09-18 | Masahiko Ichimada | 帯状疱疹後神経痛用鎮痛剤 |
| US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| JP2009516751A (ja) * | 2005-11-21 | 2009-04-23 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティー・オブ・アラバマ・フォー・アンド・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アラバマ | 神経保護のための小分子化合物を使用する方法 |
| AU2007319811A1 (en) * | 2006-11-15 | 2008-05-22 | Coda Therapeutics, Inc. | Improved methods and compositions for wound healing |
| FR2935611B1 (fr) | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| WO2012042541A2 (en) | 2010-09-30 | 2012-04-05 | Council Of Scientific & Industrial Research | Method for predicting and modeling anti-psychotic activity using virtual screening model |
| US20130096067A1 (en) | 2011-09-14 | 2013-04-18 | Norbert Perrimon | Drosophila tumor stem cell model and uses thereof |
| EP2586436A1 (en) * | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
-
2014
- 2014-07-24 HU HUE14742249A patent/HUE037122T2/hu unknown
- 2014-07-24 AU AU2014295030A patent/AU2014295030B2/en not_active Ceased
- 2014-07-24 US US14/907,221 patent/US9750734B2/en not_active Expired - Fee Related
- 2014-07-24 EP EP14742249.7A patent/EP3024458B1/en active Active
- 2014-07-24 JP JP2016528540A patent/JP6192830B2/ja not_active Expired - Fee Related
- 2014-07-24 RU RU2018122564A patent/RU2018122564A/ru not_active Application Discontinuation
- 2014-07-24 EP EP17203646.9A patent/EP3308785A3/en not_active Withdrawn
- 2014-07-24 CA CA2919140A patent/CA2919140C/en active Active
- 2014-07-24 PL PL14742249T patent/PL3024458T3/pl unknown
- 2014-07-24 PT PT147422497T patent/PT3024458T/pt unknown
- 2014-07-24 RU RU2016105971A patent/RU2661026C2/ru active
- 2014-07-24 DK DK14742249.7T patent/DK3024458T3/en active
- 2014-07-24 CA CA2997282A patent/CA2997282A1/en not_active Abandoned
- 2014-07-24 ES ES14742249.7T patent/ES2661647T3/es active Active
- 2014-07-24 BR BR112016001446A patent/BR112016001446A8/pt not_active Application Discontinuation
- 2014-07-24 KR KR1020167004739A patent/KR101754045B1/ko not_active Expired - Fee Related
- 2014-07-24 HR HRP20180487TT patent/HRP20180487T1/hr unknown
- 2014-07-24 KR KR1020177015674A patent/KR20170068629A/ko not_active Ceased
- 2014-07-24 MX MX2016001049A patent/MX365782B/es active IP Right Grant
- 2014-07-24 WO PCT/EP2014/065975 patent/WO2015011246A1/en not_active Ceased
- 2014-07-24 TR TR2018/02302T patent/TR201802302T4/tr unknown
- 2014-07-24 CN CN201480051866.3A patent/CN105579041B/zh not_active Expired - Fee Related
-
2016
- 2016-01-21 IL IL243746A patent/IL243746A/en active IP Right Grant
- 2016-01-22 MX MX2019006878A patent/MX2019006878A/es unknown
- 2016-02-19 ZA ZA2016/01146A patent/ZA201601146B/en unknown
-
2017
- 2017-03-27 JP JP2017061022A patent/JP6453931B2/ja not_active Expired - Fee Related
- 2017-08-03 US US15/667,999 patent/US20180028519A1/en not_active Abandoned
- 2017-08-29 IL IL254210A patent/IL254210B/en unknown
-
2018
- 2018-09-21 US US16/138,641 patent/US10639301B2/en not_active Expired - Fee Related
- 2018-12-13 JP JP2018233114A patent/JP6694497B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017119710A5 (https=) | ||
| RU2018122564A (ru) | Применение флекаинида в качестве антиконнексинового средства и способ потенцирования эффектов психотропных лекарственных средств | |
| AR125321A2 (es) | Compuesto cristalino, método de preparación y composición que lo comprende | |
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP2016515561A5 (https=) | ||
| BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
| HK1255500A1 (zh) | 氧固醇及其使用方法 | |
| HUE058196T2 (hu) | N-{4-[(6,7-dimetoxikinolin-4-il)oxi]fenil}-N'-(4-fluorfenil)ciklopropán-1,1-dikarboxamid kristályos szilárd sói, elõállítási eljárások és alkalmazási eljárások | |
| MX2018006903A (es) | Composicion farmaceutica. | |
| WO2014172188A3 (en) | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors | |
| EP4424374A3 (en) | Crystalline forms of tenofovir alafenamide | |
| RU2017145271A (ru) | Терапевтическое средство для фиброза | |
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| JP2016537338A5 (https=) | ||
| IL273896B2 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| CO2017008115A2 (es) | Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico | |
| WO2017220042A3 (zh) | 氨力农的药物组合物及其在高血压治疗中的应用 | |
| EP2871187A4 (en) | A NEW CONNECTION OR PHARMACEUTICALALLY SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS AN ACTIVE SUBSTANCE | |
| JP2018199643A5 (https=) | ||
| JP2016527319A5 (https=) | ||
| JP2016523943A5 (https=) |